Nuveen Dynamic Municipal

Nuveen Dynamic Municipal Opportunities Fund Common Shares of Beneficial Interest

Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. The investment objective of the Fund is to seek total return through income exempt from regular federal income taxes and capital appreciation.

Truist Securities analyst Mark Hughes maintains HCI Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCI#NYSE">HCI</a>) with a Buy and raises the price target from $93 to $110.

News

Price Target

Analyst Ratings

Truist Securities Maintains Buy on HCI Group, Raises Price Target to $110

Morgan Stanley analyst Ken Zerbe maintains First Horizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHN#NYSE">FHN</a>) with a Equal-Weight and lowers the price target from $21 to $19.5.

Morgan Stanley Maintains Equal-Weight on First Horizon, Lowers Price Target to $19.5

Genius Brands International, Inc.&#39;s&nbsp;(&quot;Genius Brands&quot;) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNUS#NASDAQ">GNUS</a>) hit animated series,&nbsp;Rainbow Rangers, is growing its viewership dramatically across multiple media worldwide, including its anchor platform&nbsp;<a href="https://www.kartoonchannel.com/?" target="_blank">Kartoon Channel</a>! in the U.S., as well as&nbsp;Netflix, Amazon Prime Video Direct, HBO Max,&nbsp;Nickelodeon Latin America, and China&#39;s largest broadcaster, CCTV, among others.
&quot;It takes time for a brand to establish itself, but we are clearly seeing that this is now occurring with&nbsp;Rainbow Rangers&nbsp;across multiple-platforms, including the recent release of season one on Netflix, where the series cracked the Top 10 of children&#39;s programs for the first time, and is consistently a top performer in Netflix categories such as &#39;Girls Take the Lead,&#39; &#39;Everyone&#39;s Watching,&#39; and &#39;Exciting TV Shows.&#39; At the same time, we are witnessing adoption across a growing base of broadcasters, including the launch of&nbsp;Rainbow Rangers&nbsp;on&nbsp;Paramount Plus&nbsp;network on August 18th,&quot; stated&nbsp;Jon Ollwerther, President of Kartoon Channel! &amp; EVP of Business Development at Genius Brands.
The broadcast success corresponds with the development of a new 2022 retail program with master toy partner, Never Wrong Toys. The retail program is based on a broad range of preschool products, initially focused in the toy category. The launch is planned to coincide with the world premiere of season three of&nbsp;Rainbow Rangers, exclusively on Kartoon Channel!
&quot;The recent success of&nbsp;Rainbow Rangers&nbsp;reminds me of the early trajectory of&nbsp;Strawberry Shortcake, which started with Hasbro Toys, but moved to Bandai Toys, and Playmates, where it eventually drove a highly successful, multi-billion dollar global licensing program,&quot; noted&nbsp;Genius Brands&#39; Chairman &amp; CEO Andy Heyward. &quot;We are taking a page from the&nbsp;Strawberry Shortcake&nbsp;playbook, with Emmy Award-winning producer Mike Maliani of that property leading the production of&nbsp;Rainbow Rangers&nbsp;in season three, introducing a twist in the new season&mdash;the addition of a&nbsp;scent&nbsp;in the storyline! Not unlike&nbsp;Strawberry Shortcake&nbsp;where all the dolls and products were scented strawberry, the dolls and products coming forth from&nbsp;Rainbow Rangers&nbsp;will be scented as well. We believe this will be a huge driver in the girls&#39; product category.&quot;&nbsp;&nbsp;
With two seasons available and season three currently in production, Genius Brands has a growing slate of media partners around the world on board for&nbsp;Rainbow Rangers, including Netflix (U.S., U.K., Canada, Australia, New Zealand, Middle East), Amazon Prime Video Direct (U.S., U.K.), Nickelodeon (U.S.), Kartoon Channel! (U.S.), HBO Max (Latin America), Nickelodeon &amp; NOGGIN (Latin America), CCTV (China), Televisa (Mexico), Treehouse (Canada), Cartoonito (Italy), Nine Network (Australia), TVNZ (New Zealand), HOP (Israel), TV2 (Hungary), NOGA (Israel), Mini Mini (Poland), Canal Panda (Portugal), Discovery Kids (Middle East), Mediacorp (Singapore), Awesome TV (Malaysia), and Pikaboo (Serbia, Montenegro, Macedonia, Slovenia, Croatia, Bosnia, Herzegovina), among others.
Kerry Phelan, Executive Vice President &amp; General Manager of Global Franchise Management at Genius Brands&nbsp;stated: &quot;Rainbow Rangers&nbsp;is a special series that is clearly resonating with young audiences around the world as we continue to build our viewership with new partners, such as Netflix, coming on board. To crack the Top 10 for the first time so quickly on Netflix, coupled with the traction we&#39;re gaining on Amazon and our own platform, Kartoon Channel!, is a testament to the strong appeal of the themes and positive messaging of the show. Our strategy continues to center around growth in viewership, which, in turn, is designed to feed our long-term merchandising strategy. We are enthusiastic about our partnership with Never Wrong Toys and are excited about developing an exciting range of preschool toys that tap into the most appealing elements of the show for 2022.&quot;
Rainbow Rangers&nbsp;is a rescue-based series that follows the adventures of seven girls who are Earth&#39;s first responders&mdash;protecting people, animals, resources, and the natural beauty of our world.&nbsp;Hilary Cherniss&nbsp;and&nbsp;Sara Jane Sluke, who were key writers in the first two seasons, are the Head Writers of season three. Multiple Emmy Award-winning director&nbsp;Michael Maliani&nbsp;directs the series, and Genius Brands&#39; Chairman &amp; CEO and multiple Emmy Award-winning producer,&nbsp;Andy Heyward, serves as executive producer.

GNUS

Genius Brands International Highlights 'Rainbow Rangers' Growth

<img alt="" src="https://static.seekingalpha.com/uploads/2021/7/30/131469-16276176063098829.jpg" style="height:325px; width:639px" />
Screen capture via Cassava Sciences&#39; video for their Simufilam Alzheimer&#39;s disease treatment.&nbsp;
Two Alzheimer&#39;s Names Come Back To Earth
In a post last week (<a href="https://www.benzinga.com/markets/penny-stocks/21/07/22132513/an-unforgettable-week-for-alzheimers-treatment-stocks-two-of-our-recent-top-names-spike-on-n" rel="nofollow">An Unforgettable Week For Alzheimer&#39;s Treatment Stocks</a>), we mentioned that two stocks with Alzheimer&#39;s disease treatments hit our top names, but both were risky:&nbsp;
<blockquote>With&nbsp;<a href="https://www.alz.org/alzheimers-dementia/facts-figures" rel="nofollow">six million</a>&nbsp;Americans suffering from Alzheimer&#39;s disease, their loved ones are desperate for effective treatments. Two of our recent top names, India Globalization Capital, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/igc#NYSE">IGC</a>) and Cassava Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sava#NASDAQ">SAVA</a>) spiked on news related to their proposed Alzheimer&#39;s treatments. Both are risky stocks, so we&#39;ll look ways investors can hold them while limiting their risk below.
</blockquote>
Since then, both stocks are still above where they were when they first hit our top names, but both are down double digits over the last week.&nbsp;
<img alt="Chart" src="https://static.seekingalpha.com/uploads/2021/7/30/saupload_6d20a3a8596a6f9183aa90585336129a.png" style="height:366px; width:635px" />
&nbsp;
This is why we suggest hedging. Let&#39;s look at how hedging ameliorated these drops in both of these stocks.&nbsp;
Cassava Sciences
Cassava Sciences was one of seven names in the concentrated portfolio we presented in our premarket post early last week,&nbsp;<a href="https://www.benzinga.com/news/small-cap/21/07/22072144/building-a-bear-proof-portfolio-investing-safely-up-as-the-fear-greed-index-approaches-early-2020-" rel="nofollow">Building A Bear-Proof Portfolio</a>.&nbsp;
<img alt="" src="https://static.seekingalpha.com/uploads/2021/7/20/131469-16267655875463707.png" />
<img alt="" src="https://static.seekingalpha.com/uploads/2021/7/20/131469-16267656520740342.png" />
Screen captures via&nbsp;<a href="https://portfolioarmor.com/" rel="nofollow">Portfolio Armor</a>&nbsp;as of July 19th&#39;s close.
Here&#39;s how that portfolio has done since.&nbsp;
<a href="https://static.seekingalpha.com/uploads/2021/7/30/131469-1627621280592187_origin.png" rel="lightbox"><img alt="" src="https://static.seekingalpha.com/uploads/2021/7/30/131469-1627621280592187.png" /></a>
<a href="https://static.seekingalpha.com/uploads/2021/7/30/131469-1627621411254165_origin.png" rel="lightbox"><img alt="" src="https://static.seekingalpha.com/uploads/2021/7/30/131469-1627621411254165.png" /></a>
Steady as she goes for this hedged portfolio, despite SAVA dropping nearly 24% on Thursday. The hedges smoothed things out.&nbsp;
India Globalization Capital&nbsp;
This was our number one name on March 18th.&nbsp;
<img alt="" src="https://static.seekingalpha.com/uploads/2021/3/18/131469-16161214119053028.png" />
Screen capture via Portfolio Armor on 3/18/2021.
Last week, we presented this hedge for it.&nbsp;
<img alt="" src="https://static.seekingalpha.com/uploads/2021/7/23/131469-1627029586342199.jpg" style="height:459px; width:340px" />
<img alt="" src="https://static.seekingalpha.com/uploads/2021/7/23/131469-16270296249596155.jpg" style="height:398px; width:340px" />
Screen captures via the Portfolio Armor&nbsp;iPhone app&nbsp;on July 19th.&nbsp;
Since then, IGC is down 36%, unhedged. How much would you be down if you were hedged with the collar above? Let&#39;s work it out:&nbsp;
What you started with
10,000 shares of IGC at $2.80 for $28,000
+ $7,000 in IGC puts
- $9,000 in IGC calls (i.e., you would have had to pay that much to buy-to-close the short call leg of the collar).&nbsp;
= $26,000&nbsp;
What you had as of Thursday&#39;s close
10,000 shares of IGC at $1.80 for $18,000
+ $7,750 in IGC puts (using the midpoint of the bid-ask at Thursday&#39;s close).&nbsp;
- $3,750 in IGC calls (using the midpoint of the spread again)
= $22,000
The bottom line
The stock dropped from $28,000 to $18,000, a drop of about 36%, but your hedged position dropped from $28,000 to $22,000, a drop of about 21%. Remember, the hedge was designed to protect against a &gt;25% decline, so this is more protection than promised.&nbsp;
If You Want To Stay In Touch With The Author
You can follow&nbsp;on Twitter&nbsp;<a href="https://twitter.com/portfolioarmor" rel="nofollow">here</a>, subscribe to&nbsp;the email list&nbsp;<a href="http://eepurl.com/hAeIX5" rel="nofollow">here</a>, and subscribe to&nbsp;the YouTube channel&nbsp;<a href="https://accounts.google.com/ServiceLogin?service=youtube&amp;uilel=3&amp;passive=true&amp;continue=https%3A%2F%2Fwww.youtube.com%2Fsignin%3Faction_handle_signin%3Dtrue%26app%3Ddesktop%26hl%3Den%26next%3D%252Fresults%253Fsearch_query%253Dportfolio%252Barmor%26continue_action%3DQUFFLUhqbjJnV1NlSnFKTjI4aEppVlpzRE12VU82cDlOQXxBQ3Jtc0ttSTFxU3djNzQxenFnTzd6amNLNkEyVDJxTE5Na25jYXF1UGRBRk1UUFI3MWtBakZsUUFrZDkwR1hwOFdydzJMenpEQlByYnAtNjJ4YTJYLUdlQ2RuUHJKTmNna3R1enpGakZNRUgzd21TTGJTWVdBU3hJVURjYXpxWHczRm1LYkJNNGN6OWtmT3RSYUUzdldIMW0wZ3hxZkQyajVMUHlUdFNGSmhWemtMUUR1U2hjbmJZdFpIMFV0czZvSWNFMUN3YmROcWtwV0NXV3cySnY1NzRXenQ1U3RwUzNR&amp;hl=en" rel="nofollow">here</a>.

Penny Stocks

SAVA

A Forgettable Week For Alzheimer's Treatment Stocks: Two Of Our Top Names Come Back To Earth. This Is Why We Hedge.

<a href="https://ffj-online.org/2021/08/02/freedom-holding-the-red-flag-factory-in-belize/" title="https://ffj-online.org/2021/08/02/freedom-holding-the-red-flag-factory-in-belize/">https://ffj-online.org/2021/08/02/freedom-holding-the-red-flag-factory-in-belize/</a>

Movers

Trading Ideas

FRHC

Freedom Holding Shares Fall Sharply; Traders Circulate The Foundation for Financial Journalism Report Titled 'Freedom Holding: The Red Flag Factory in Belize'

Morgan Stanley analyst Ken Zerbe maintains East West Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NASDAQ">EWBC</a>) with a Overweight and raises the price target from $90 to $98.

EWBC

Morgan Stanley Maintains Overweight on East West Bancorp, Raises Price Target to $98

Morgan Stanley analyst Ravi Shanker maintains Echo Global Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECHO#NASDAQ">ECHO</a>) with a Equal-Weight and raises the price target from $29 to $30.

ECHO

Morgan Stanley Maintains Equal-Weight on Echo Global Logistics, Raises Price Target to $30

<ul>
<li>The&nbsp;<a class="editor-rtfLink" href="https://www.prnewswire.com/news-releases/fda-clears-vaxarts-ind-application-for-s-only-oral-tablet-covid-19-vaccine-candidate-301345771.html" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">FDA has signed off</a>&nbsp;Vaxart Inc&#39;s&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vxrt#NASDAQ">VXRT</a>) Investigational New Drug application for an S-only oral tablet SARS-CoV-2 vaccine candidate.</li>
<li>&quot;This is great news because it allows us to move forward with our first S-only vaccine construct,&quot; said Andrei Floroiu, Vaxart&#39;s Chief Executive Officer. &quot;<a class="editor-rtfLink" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3245694-1&amp;h=871169869&amp;u=https%3A%2F%2Finvestors.vaxart.com%2Fnews-releases%2Fnews-release-details%2Fvaxart-reports-first-quarter-2021-financial-results-and-provides&amp;a=As+we+said+at+the+end+of+the+first+quarter" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">As we said at the end of the first quarter</a>, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial.&quot;</li>
<li>&quot;This new clinical trial will allow us to compare the S-only and S+N vaccine candidates and put us in a position to decide which approach offers the best way forward for our COVID-19 vaccine development program, particularly in the face of emerging variant strains.&quot;</li>
<li>The Phase 2 clinical trial with the S-only construct is expected to start in 2H of 2021.</li>
<li>Related:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/21/05/20931256/vaxart-stock-is-surging-as-its-oral-covid-19-vaccine-can-potentially-trigger-immunity-against-var" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">Vaxart&#39;s Oral COVID-19 Vaccine Can Potentially Trigger Immunity Against Variants</a>.</li>
<li>Price Action:&nbsp;VXRT shares are up 12% at $8.05 during the premarket session on the last check Monday.</li>
<li>Related content: Benzinga&#39;s Full&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/calendars/fda#historical" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">FDA Calendar</a>.</li>
</ul>

Biotech

Long Ideas

Health Care

Small Cap

General

VXRT

Vaxart Stock Is Trading Higher As FDA Clears Mid-Stage Trial For S-Only Oral COVID-19 Vaccine Candidate

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">46.65</td>
<td align="right">0.27</td>
<td align="right">0.58</td>
<td>3.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">36.70</td>
<td align="right">0.18</td>
<td align="right">0.49</td>
<td>147.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">84.42</td>
<td align="right">0.40</td>
<td align="right">0.47</td>
<td>3.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">154.03</td>
<td align="right">0.63</td>
<td align="right">0.41</td>
<td>32.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">103.72</td>
<td align="right">0.36</td>
<td align="right">0.34</td>
<td>13.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">132.54</td>
<td align="right">0.39</td>
<td align="right">0.29</td>
<td>7.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">66.13</td>
<td align="right">0.16</td>
<td align="right">0.24</td>
<td>13.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">49.40</td>
<td align="right">0.01</td>
<td align="right">0.02</td>
<td>81.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">71.53</td>
<td align="right">0.02</td>
<td align="right">0.02</td>
<td>17.0K</td>
</tr>
</tbody>
</table>
No loser in today&#39;s Pre-market session.
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> these sector movers alerts can help traders understand macro-level market trends. Traders often look for sector movers to provide high-level analysis on which sectors are over- or under-performing to make better investing decisions on exchange traded funds (ETFs) or individual tickers in those sectors.
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

ETFs

XLRE

Leading And Lagging Sectors For August 2, 2021

RACE

Ferrari Conference Call: Chairman Says Electrification Will Allow Co To Make Even More Distinctive Products

<ul>
<li>Jeld-Wen Holding Inc&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jeld#NYSE">JELD</a>) reported second-quarter revenue growth of 25.5% year-over-year to $1.25 billion, beating the consensus of $1.16 billion.</li>
<li>Core revenue increased by 19% and grew in all three reporting segments, driven by an acceleration in volume and price realization.</li>
<li>Sales by segments: North America $740.1 million (+21.7% Y/Y), Europe $349.7 million (33.7% Y/Y) and Australasia $155.9 million (+27.1% Y/Y).</li>
<li>Adjusted EBITDA increased by 17.9% Y/Y to $148.2 million, and margin contracted by 80 bps to 11.9%.</li>
<li>Gross profit increased 33.5% to $291.9 million and the gross margin expanded by 140 bps to 23.4%.</li>
<li>Operating income more than doubled to $102.1 million for the quarter, and the margin expanded by 315 bps to 8.2%.</li>
<li>Adjusted EPS improved to $0.59 from $0.47 in 2Q20, missing the consensus of $0.61.</li>
<li>Jeld-Wen generated cash from operating activities year-to-date of $40.7 million, increasing by $2.4 million from $38.3 million a year ago, with free cash flow use of $4 million.</li>
<li>On July 27, 2021, the company authorized an increase to its existing share repurchase program to purchase up to a total of $400 million of its common stock. During the quarter, the company repurchased 1.17 million shares for $33.7 million.</li>
<li>Additionally, Jeld-Wen has also commenced a process for the divestiture of its Towanda, PA operations. It has decided not to appeal the decision by the U.S. Court of Appeals for the Fourth Circuit, which upheld the district court&rsquo;s divestiture ruling in the litigation between the company and&nbsp;Steves and Sons, Inc.</li>
<li>The company&rsquo;s total liquidity, including cash and cash equivalents and undrawn committed credit facilities, stood at $1.02 billion as of June 26, 2021.</li>
<li>FY21 Outlook:&nbsp;Jeld-Wen Holding expects net revenue growth of 12%-14%, compared to the prior view of 8.0%-11.0%.</li>
<li>It tightened its Adjusted EBITDA outlook to $510 million - $535 million, compared to the prior $505 million - $535 million.</li>
<li>Price Action:&nbsp;JELD shares are down 0.30% at $26.40 during the premarket session on the last check Monday.</li>
</ul>

Earnings

Guidance

Buybacks

JELD

Jeld-Wen Holding Reports Mixed Q2 Results, Begins Process To Divest Towanda Operations On Court Order

Citigroup analyst Michael Rollins upgrades Consolidated Comms Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSL#NASDAQ">CNSL</a>) from Sell to Neutral.

Upgrades

CNSL

Citigroup Upgrades Consolidated Comms Hldgs to Neutral

Europe-based Kanabo Group Plc (LSE: KNB),&nbsp;the first medical cannabis company to IPO on London Stock Exchange, has signed a letter of intent&nbsp;to acquire Materia -&nbsp;a processor and distributor of medical cannabis and CBD products across Europe&nbsp;for an undisclosed amount. The merger would create the&nbsp;largest publicly traded cannabis company in the EU.
According to management, Materia infrastructure supplements that of Kanabo, and will be crucial to expanding and strengthening the company&rsquo;s existing supply value chain in the medical cannabis and CBD realms.
&ldquo;We are excited at the prospect of joining forces with Kanabo&rsquo;s team. As the first medical cannabis company approved to list on the London Stock Exchange, Kanabo&rsquo;s ambition to be a market leader matches our own and we believe that our combined infrastructure will generate significant value for our shareholders, partners, customers and patients,&rdquo; Materia&rsquo;s Deepak Anand told Benzinga.
Pre-merger, Kanabo&#39;s&nbsp;valuation stands slightly below $100 million.&nbsp;With a focus on distributing cannabis-derived products for medical patients&nbsp;and non-THC products for CBD consumers, Kanabo has conducted extensive research &amp; development in order to produce high-quality cannabis extract formulas, innovative medical-grade vaporizers&nbsp;and various non-smoking consumption solutions.
Encuentra nuestro contenido en Espa&ntilde;ol en El Planteo:
<ul>
<li><a href="https://elplanteo.com/marihuana-recreativa-europa/">Cannabis Recreativo en Europa: Comienza la Cuenta Regresiva Final</a></li>
<li><a href="https://elplanteo.com/curaleaf-cantor-europa-eeuu-charla/">Curaleaf en Europa y EEUU, &iquest;Qu&eacute; Depara el Futuro Para la Empresa de Cannabis?</a></li>
</ul>

Cannabis

Markets

Kanabo's Acquisition of Materia Will Create Europe's Largest Public Cannabis Company

<ul>
<li>Arcturus Therapeutics Holdings Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arct#NASDAQ">ARCT</a>) has collaborated with&nbsp;Vinbiocare&nbsp;to&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/08/b22270878/arcturus-therapeutics-collaborates-with-vingroup-to-establish-manufacturing-facility-in-vietnam-fo" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">establish a manufacturing facility in Vietnam</a>&nbsp;for its investigational COVID-19 vaccines for sale and use within Vietnam.</li>
<li>Under the terms of the arrangement, Vinbiocare will, with consultation from Arcturus, build out a manufacturing facility in Vietnam.&nbsp;</li>
<li>Arcturus will provide Vinbiocare access to proprietary technologies and processes to manufacture Arcturus&#39; investigational COVID-19 vaccines.&nbsp;</li>
<li>Arcturus will provide Vinbiocare with an exclusive license to manufacture the vaccines solely for distribution in Vietnam.&nbsp;</li>
<li>Technology transfer is underway.</li>
<li>Vinbiocare will make an upfront payment of $40 million and be responsible for costs associated with the technology transfer.&nbsp;</li>
<li>Vinbiocare will also pay for mRNA drug substances supplied by Arcturus and royalties on vaccines produced at the facility.</li>
<li>Arcturus COVID-19 vaccine candidate utilizes self-transcribing and replicating (STARR) mRNA technology and is delivered with Arcturus&#39;s lipid-mediated delivery system called LUNAR delivery system.</li>
<li>Price Action:&nbsp;ARCT shares are up 4.92% at $32.85 during the premarket session on the last check Monday.</li>
</ul>

Contracts

ARCT

Arcturus Therapeutics Stock Jumps On Establishment Of COVID-19 Vaccine Plant In Vietnam

Goldman Sachs downgrades Lufax Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LU#NYSE">LU</a>) from Buy to Neutral and lowers the price target from $20.3 to $9.8.

Downgrades

Goldman Sachs Downgrades Lufax Holding to Neutral, Lowers Price Target to $9.8

Barrington Research analyst James Goss upgrades Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) from Market Perform to Outperform and announces $115 price target.

Barrington Research Upgrades Dolby Laboratories to Outperform, Announces $115 Price Target

From Ferrari Q2 Earnings Conference Call: Jun. Was Best Month Ever For Orders

Invacare Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVC#NYSE">IVC</a>) announced today the launch of the Invacare&reg; AVIVA&reg; STORM RX&trade; power wheelchair, setting a new standard for rear-wheel drive power mobility.
&quot;We are excited to introduce the next generation of Invacare power mobility products with the AVIVA STORM RX, an innovative leap forward in rear-wheel drive power wheelchairs. The AVIVA brand has a unique identity that conveys a promise of superior technology, design and performance. This launch represents yet another step forward for our end-users while further differentiating Invacare&#39;s product portfolio,&quot; said Joost Beltman, senior vice president and general manager, North America for Invacare.
Design
With its sleek base, the flared front end supports use of the center mount foot platform for overall turning radius reduction, enables the legs to tuck under the chair up to 7˚, allows a user to get closer to their environment, and facilitates easier stand pivot transfers.
A unique open stack design allows the tires, wheels and hubs, gearboxes, and motors to be easily removed. And, with all electronics placed at the rear of the unit, wiring and connections are easy to see and access with the rear cover removed.
Expanded color options including eight new shroud colors and eleven wheel-insert colors allows a user to customize their wheelchair and let their personality shine.
Technology
Rehab-redefining LiNX&reg; technology continues to enhance the set-up process with new and improved features. From pre-set programming parameters, to live wireless programming, to integration with ASL specialty controls, set-up is as simple as turning on the LiNX remote.
Standard LED lighting system helps users illuminate the area in front of them.
Adaptive load compensation interprets, learns, and adapts the motors to changes and helps to ensure the drive of the power wheelchair is optimized and balanced over time.
Performance
With a short wheelbase and narrow width, the AVIVA STORM RX gives a compact base footprint for excellent maneuverability. At the same time, users can choose between a 5.8 mph or 7.5 mph high performance motor package.
The all new patent-pending Invacare&reg; SureGrip&trade; suspension system helps provide a smooth and silent driving experience indoors and outdoors. A Rear anti-tipper utilizes a shock absorber to help respond to vibrations and noise, providing a smoother, quieter ride. The drive motor is pushed down for better traction as the rear anti-tipper is engaged over a bump and the front caster bearing has an elastomeric dampener to help reduce vibrations and impacts.
To find out more about the Invacare AVIVA Storm RX Power Wheelchair, visit&nbsp;<a href="https://rehab.invacare.com/">https://rehab.invacare.com/</a>

Invacare Corporation Highlights Invacare AVIVA STORM RX Wheelchair

<ul>
<li>Immunovant Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imvt#NASDAQ">IMVT</a>) has&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/08/g22271444/immunovant-receives-200-million-strategic-investment-from-roivant-sciences" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">received a $200 million strategic investment</a>&nbsp;from&nbsp;Roivant Sciences&nbsp;that the Company will use to advance IMVT-1401 in multiple indications.</li>
<li>Roivant has purchased around 17 million shares of Immunovant&#39;s shares at $11.75 per share.&nbsp;</li>
<li>After giving effect to the investment, Immunovant has a pro forma cash balance of approximately $600 million, and Roivant has increased its ownership stake in Immunovant from 57.5% to 63.8%.</li>
<li>IMVT-1401, a fully human anti-FcRn monoclonal antibody, is Immunovant&#39;s lead candidate.</li>
<li>&quot;We are excited to announce this significant investment by Roivant, which will expedite our development of IMVT-1401 for a wide range of autoimmune disorders,&quot; said Dr. Pete Salzmann, Chief Executive Officer of Immunovant. &quot;Over the next 12 months, we plan to initiate a pivotal trial for myasthenia gravis, resume our trials in WAIHA and TED and initiate at least two additional clinical studies, including another pivotal trial in 2022.&quot;</li>
<li>Price Action: IMVT shares are down 24.5% at $7.90 during the premarket session on the last check Monday.</li>
</ul>

Short Ideas

Financing

Offerings

IMVT

Immunovant Stock Plunges On $200M Equity Investment From Roivant To Support IMVT-1401 Development

Argus Research analyst David Toung downgrades Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) from Buy to Hold.

TDOC

Argus Research Downgrades Teladoc Health to Hold

Intraday Update

Stocks That Hit 52-Week Highs On Tuesday

ADBE

ALKS

ALTR

AMEH

AMZN

ARES

ASAN

ATTO

BLIN

BRKR

BSIG

CHTR

CLAR

CLSD

COST

CPRT

CRVL

CRWD

DAVA

DECK

DRNA

EPSN

FTNT

FWONA

FWONK

GNRC

GOOG

GOOGL

GRMN

HUBS

IDXX

INFO

INTU

INVH

ISEE

ISRG

JCOM

KVSB

LBRDK

LSPD

MNDY

MRIN

MSCI

MSFT

NDMO

NMCO

NVDA

OSAT

PAYX

PFSW

PTRS

RELX

RVLV

SHEN

SMLP

SPGI

SYNA

TROW

VEON

VRSN

ZBRA

Nuveen Credit-Focused Muni CEFs Remain Attractive

Nuveen has successfully completed the initial public offering of the Nuveen Dynamic Municipal Opportunities Fund. The investment objective of the Fund is to seek total return through income exempt from regular federal income taxes and capital appreciation. The Fund seeks to achieve its investment objective by investing in municipal securities, the interest on which is exempt from regular U.S. federal income tax.


The fund will begin trading on the New York Stock Exchange (NYSE) today, under the symbol NDMO.


The fund raised $780 million in its common share offering, excluding any exercise of the underwriters' option to purchase additional shares.


If the underwriters exercise that option in full, the fund will have raised approximately $889 million.


Shares of closed-end investment companies, like the fund, usually trade on a national stock exchange. Similar to stocks, the fund's share price will fluctuate with market conditions and, at the time of sale, may be worth more or less than the original investment. Shares of closed-end funds often trade at a discount to their net asset value.


For more information, please visit Nuveen's CEF homepage <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.nuveen.com%2Fclosed-end-funds&amp;esheet=52274039&amp;newsitemid=20200827005204&amp;lan=en-US&amp;anchor=www.nuveen.com%2Fclosed-end-funds&amp;index=1&amp;md5=c2697c66c389db651b91b034fa12ed99" shape="rect">www.nuveen.com/closed-end-funds</a>.


About Nuveen


Nuveen, the investment manager of TIAA, offers a comprehensive range of outcome-focused investment solutions designed to secure the long-term financial goals of institutional and individual investors. Nuveen has $1 trillion in assets under management as of 30 June 2020 and operations in 27 countries. Its investment specialists offer deep expertise across a comprehensive range of traditional and alternative investments through a wide array of vehicles and customized strategies. For more information, please visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.nuveen.com&amp;esheet=52274039&amp;newsitemid=20200827005204&amp;lan=en-US&amp;anchor=www.nuveen.com&amp;index=2&amp;md5=fb2bd4b391088f5c4ecfc2b26fc71f16" shape="rect">www.nuveen.com</a>.


Nuveen Securities, LLC, member FINRA and SIPC.


Investors should consider the investment objective and policies, risk considerations, charges and expenses of the fund carefully before investing. For a prospectus which contains this and other information relevant to an investment in the fund, please contact your securities representative or Nuveen Securities, LLC, 333 W. Wacker Drive, Chicago, IL 60606. Investors should read the prospectus carefully before they invest or send money.


This document is not an offer to sell securities and is not soliciting an offer to buy securities in any jurisdiction where the offer or sale is not permitted.


Income exempt from federal income tax may be subject to state and local taxes and the alternative minimum tax. Capital gains, if any, will be subject to capital gains tax.


Key Risk Considerations:


Municipal Securities Market Risk. The amount of public information available about the municipal securities in the fund's portfolio is generally less than that for corporate equities or bonds, and the investment performance of the fund may therefore be more dependent on the analytical abilities of the fund's sub-adviser than if the fund were a stock fund or taxable bond fund. The secondary market for municipal securities, particularly the below investment grade municipal securities in which the fund may invest, also tends to be less well-developed or liquid than many other securities markets, which may adversely affect the fund's ability to sell its municipal securities at attractive prices. In addition, the market for below investment grade municipal securities has experienced in the past, and may experience in the future, periods of significant volatility, which could negatively impact the value of the municipal securities in the fund's portfolio and the market price of the Common Shares.


Issuer Credit Risk. Issuers of municipal securities in which the fund may invest may default on their obligations to pay principal or interest when due. This non-payment would result in a reduction of income to the fund, a reduction in the value of a municipal security experiencing non-payment and, potentially, a decrease in the net asset value of the fund. To the extent that the credit rating assigned to a municipal security in the fund's portfolio is downgraded, the market price and liquidity of such security may be adversely affected.


Below Investment Grade Risk. Securities of below investment grade quality are regarded as having speculative characteristics with respect to the issuer's capacity to pay interest and repay principal and may be subject to higher price volatility and default risk than investment grade securities of comparable terms and duration. Issuers of lower grade securities may be highly leveraged and may not have available to them more traditional methods of financing. The prices of these lower grade securities are typically more sensitive to negative developments, such as a decline in the issuer's revenues or a general economic downturn. The secondary market for lower rated securities may not be as liquid as the secondary market for more highly rated securities, a factor which may have an adverse effect on the fund's ability to dispose of a particular security. If a below investment grade security goes into default, or its issuer enters bankruptcy, it might be difficult to sell that security in a timely manner at a reasonable price. 


Interest Rate Risk. Generally, when market interest rates rise, bond prices fall, and vice versa. Interest rate risk is the risk that the municipal securities in the fund's portfolio will decline in value because of increases in market interest rates. As interest rates decline, issuers of municipal securities may prepay principal earlier than scheduled, forcing the fund to reinvest in lower-yielding municipal securities and potentially reducing the fund's income. As interest rates increase, slower than expected principal payments may extend the average life of municipal securities, potentially locking in a below-market interest rate and reducing the fund's value. In typical market interest rate environments, the prices of longer-term municipal securities generally fluctuate more than prices of shorter-term municipal securities as interest rates change.


The information contained on the Nuveen website is not a part of this press release.


EPS-1310234PR-E0820X
<img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20200827005204r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img>View source version on businesswire.com: <a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20200827005204/en/" rel="nofollow">https://www.businesswire.com/news/home/20200827005204/en/</a>

Press Releases

Nuveen Dynamic Municipal Opportunities Fund Attracts $780 Million

The Nuveen Dynamic Municipal Opportunities Fund (NYSE:<a class="ticker" href="/stock/NDMO#NYSE">NDMO</a>) declared its initial monthly managed distribution of $0.0765 per share. The fund began trading on the NYSE on August 27, 2020. This first distribution reflects an annualized distribution rate of 6.12 percent based on the fund's $15.00 per share IPO price.

The following dates apply to today&#39;s monthly distribution declaration:
<table xmlns="http://www.w3.org/1999/xhtml" cellspacing="0" class="bwtablemarginb bwblockalignl">
<tr xmlns="http://www.w3.org/1999/xhtml">
<td xmlns="http://www.w3.org/1999/xhtml" class="bwvertalignt bwpadl0" rowspan="1" colspan="1">
Record Date

</td>
<td xmlns="http://www.w3.org/1999/xhtml" class="bwvertalignt bwpadl0" rowspan="1" colspan="1">
 

</td>
<td xmlns="http://www.w3.org/1999/xhtml" class="bwvertalignt bwpadl4" rowspan="1" colspan="1">
October 15, 2020

</td>
</tr>
<tr xmlns="http://www.w3.org/1999/xhtml">
<td xmlns="http://www.w3.org/1999/xhtml" class="bwvertalignt bwpadl0" rowspan="1" colspan="1">
Ex-Dividend Date

</td>
<td xmlns="http://www.w3.org/1999/xhtml" class="bwvertalignt bwpadl0" rowspan="1" colspan="1">
 

</td>
<td xmlns="http://www.w3.org/1999/xhtml" class="bwvertalignt bwpadl4" rowspan="1" colspan="1">
October 14, 2020

</td>
</tr>
<tr xmlns="http://www.w3.org/1999/xhtml">
<td xmlns="http://www.w3.org/1999/xhtml" class="bwvertalignt bwpadl0" rowspan="1" colspan="1">
Payable Date

</td>
<td xmlns="http://www.w3.org/1999/xhtml" class="bwvertalignt bwpadl0" rowspan="1" colspan="1">
 

</td>
<td xmlns="http://www.w3.org/1999/xhtml" class="bwvertalignt bwpadl4" rowspan="1" colspan="1">
November 2, 2020

</td>
</tr>
</table><table xmlns="http://www.w3.org/1999/xhtml" cellspacing="0" class="bwtablemarginb bwblockalignl">
<tr xmlns="http://www.w3.org/1999/xhtml">
<td xmlns="http://www.w3.org/1999/xhtml" class="bwvertalignb bwpadl0" rowspan="1" colspan="1">
Ticker

</td>
<td xmlns="http://www.w3.org/1999/xhtml" rowspan="1" colspan="1"></td>
<td xmlns="http://www.w3.org/1999/xhtml" class="bwvertalignb bwpadl2" rowspan="1" colspan="1">
Exchange

</td>
<td xmlns="http://www.w3.org/1999/xhtml" rowspan="1" colspan="1"></td>
<td xmlns="http://www.w3.org/1999/xhtml" class="bwvertalignb bwpadl2" rowspan="1" colspan="1">
Fund Name

</td>
<td xmlns="http://www.w3.org/1999/xhtml" rowspan="1" colspan="1"></td>
<td xmlns="http://www.w3.org/1999/xhtml" class="bwvertalignb bwsinglebottom bwpadl0 bwalignc" rowspan="1" colspan="1">
Monthly Distribution
 Amount Per Share 

</td>
</tr>
<tr xmlns="http://www.w3.org/1999/xhtml">
<td xmlns="http://www.w3.org/1999/xhtml" class="bwvertalignb bwpadl0" rowspan="1" colspan="1">
NDMO

</td>
<td xmlns="http://www.w3.org/1999/xhtml" rowspan="1" colspan="1"></td>
<td xmlns="http://www.w3.org/1999/xhtml" class="bwvertalignb bwpadl2" rowspan="1" colspan="1">
NYSE

</td>
<td xmlns="http://www.w3.org/1999/xhtml" rowspan="1" colspan="1"></td>
<td xmlns="http://www.w3.org/1999/xhtml" class="bwvertalignb bwpadl2" rowspan="1" colspan="1">
Nuveen Dynamic Municipal Opportunities Fund

</td>
<td xmlns="http://www.w3.org/1999/xhtml" rowspan="1" colspan="1"></td>
<td xmlns="http://www.w3.org/1999/xhtml" class="bwvertalignb bwpadl0 bwpadr0 bwalignc" rowspan="1" colspan="1">
$0.0765

</td>
</tr>
</table>
The goal of the fund's managed distribution program is to provide shareholders with relatively consistent and predictable cash flow by systematically converting expected long-term return potential into regular distributions. Historical closed-end fund distribution sources have included net investment income, realized gains and return of capital. If a distribution includes anything other than net investment income, the fund provides a notice of the best estimate of its distribution sources at that time which may be viewed at <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.nuveen.com%2FCEFdistributions&amp;esheet=52297156&amp;newsitemid=20200929005922&amp;lan=en-US&amp;anchor=www.nuveen.com%2FCEFdistributions&amp;index=1&amp;md5=78f36f8678617438e3ad1bf6af423a89" shape="rect">www.nuveen.com/CEFdistributions</a>. These estimates may not match the final tax characterization contained in shareholders' 1099-DIV forms after the end of the year.

Under a Managed Distribution policy, the fund seeks to maintain a stable regular distribution amount that, over the long term, matches the fund's total distributions paid to its total return. Investors should not draw any conclusions about a fund's past or future investment performance from its current distribution rate or from the terms of its Managed Distribution Policy. Actual returns likely will differ from projected long-term returns, (and therefore a fund's distribution rate, also), at least over shorter time periods. Over a specific timeframe, a fund's net asset value will increase (if returns exceed distributions), or decrease (if distributions exceed returns), by the difference between actual returns and total distributions.

A return of capital is a non-taxable distribution of a portion of the fund's capital. When a fund's returns exceed distributions, return of capital may represent portfolio gains earned, but not realized as a taxable capital gain. In periods when a fund's returns fall short of distributions, it will represent a portion of the investors' original principal unless the shortfall is offset during other time periods over the life of the investment (previous or subsequent) when the fund's total return exceeds distributions.

For more information, please visit Nuveen's CEF homepage <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.nuveen.com%2Fclosed-end-funds&amp;esheet=52297156&amp;newsitemid=20200929005922&amp;lan=en-US&amp;anchor=www.nuveen.com%2Fclosed-end-funds&amp;index=2&amp;md5=23b9372324c7743a6eb67664f2f808a5" shape="rect">www.nuveen.com/closed-end-funds</a>.

About Nuveen

Nuveen, the investment manager of TIAA, offers a comprehensive range of outcome-focused investment solutions designed to secure the long-term financial goals of institutional and individual investors. Nuveen has $1 trillion in assets under management as of 30 June 2020 and operations in 27 countries. Its investment specialists offer deep expertise across a comprehensive range of traditional and alternative investments through a wide array of vehicles and customized strategies. For more information, please visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.nuveen.com&amp;esheet=52297156&amp;newsitemid=20200929005922&amp;lan=en-US&amp;anchor=www.nuveen.com&amp;index=3&amp;md5=bd048b386f1748a8d8ba9f8c4f0ebd60" shape="rect">www.nuveen.com</a>.

Nuveen Securities, LLC, member FINRA and SIPC.

The information contained on the Nuveen website is not a part of this press release.

EPS-1341408PR-E0920X
<img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20200929005922r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img>View source version on businesswire.com: <a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20200929005922/en/" rel="nofollow">https://www.businesswire.com/news/home/20200929005922/en/</a>

Nuveen Dynamic Municipal Opportunities Fund Declares Initial Distribution

Certain Nuveen Closed-End Funds Announce the Board's Approval of Amended and Restated By-Laws of the Funds

Recent Quotes

Related Companies

Nuveen Dynamic Municipal Frequently Asked Questions

How do I buy Nuveen Dynamic Municipal (NDMO) stock?

Who are Nuveen Dynamic Municipal's (NDMO) competitors?

What is the target price for Nuveen Dynamic Municipal (NDMO) stock?

Current Stock Price for Nuveen Dynamic Municipal (NDMO)?

Does Nuveen Dynamic Municipal (NDMO) pay a dividend?

When is Nuveen Dynamic Municipal (NYSE:NDMO) reporting earnings?

Is Nuveen Dynamic Municipal (NDMO) going to split?

What sector and industry does Nuveen Dynamic Municipal (NDMO) operate in?